HALO vs JHG Comparison

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Janus Henderson Group provides investment management services to retail intermediary (49% of managed assets), self-directed (20%) and institutional (31%) clients. At the end of 2025, active equities (52%), fixed-income (32%), balanced (12%) and alternative (4%) investment platforms constituted the company's $493.2 billion in assets under management. Janus Henderson sources most of its managed assets from clients in North America (65%), with customers from Europe, the Middle East, Africa, and Latin America (26%) and the Asia-Pacific region (9%) accounting for the remainder.